HK1207006A1 - Daptomycin formulations and uses thereof - Google Patents
Daptomycin formulations and uses thereof Download PDFInfo
- Publication number
- HK1207006A1 HK1207006A1 HK15107795.5A HK15107795A HK1207006A1 HK 1207006 A1 HK1207006 A1 HK 1207006A1 HK 15107795 A HK15107795 A HK 15107795A HK 1207006 A1 HK1207006 A1 HK 1207006A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- daptomycin formulations
- lyophilised
- daptomycin
- formulations
- useful
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261699570P | 2012-09-11 | 2012-09-11 | |
| US201261699570P | 2012-09-11 | ||
| US201361839699P | 2013-06-26 | 2013-06-26 | |
| US201361839699P | 2013-06-26 | ||
| PCT/IB2013/002191 WO2014041425A1 (fr) | 2012-09-11 | 2013-09-11 | Formulations de daptomycine et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1207006A1 true HK1207006A1 (en) | 2016-01-22 |
Family
ID=50277707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15107795.5A HK1207006A1 (en) | 2012-09-11 | 2013-09-11 | Daptomycin formulations and uses thereof |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US9655946B2 (fr) |
| EP (2) | EP4066849B1 (fr) |
| AU (2) | AU2013316779A1 (fr) |
| BR (1) | BR112015005400B1 (fr) |
| CA (1) | CA2884484C (fr) |
| CL (1) | CL2015000608A1 (fr) |
| CY (1) | CY2200004T2 (fr) |
| DE (1) | DE13837694T1 (fr) |
| DK (1) | DK2895187T1 (fr) |
| ES (2) | ES3018415T3 (fr) |
| HK (1) | HK1207006A1 (fr) |
| HU (2) | HUE071031T2 (fr) |
| IL (1) | IL237652B (fr) |
| MX (1) | MX366122B (fr) |
| NZ (3) | NZ742241A (fr) |
| PL (1) | PL4066849T3 (fr) |
| SA (1) | SA515360129B1 (fr) |
| SG (1) | SG11201506113WA (fr) |
| TN (1) | TN2015000090A1 (fr) |
| WO (1) | WO2014041425A1 (fr) |
| ZA (1) | ZA201502310B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013316779A1 (en) * | 2012-09-11 | 2015-04-02 | Hospira Australia Pty Ltd. | Daptomycin formulations and uses thereof |
| JOP20130273B1 (ar) | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
| US10933019B2 (en) | 2016-10-21 | 2021-03-02 | Xellia Pharmaceuticals Aps | Liquid formulations of daptomycin |
| CA3070660A1 (fr) | 2017-08-31 | 2019-03-07 | Xellia Pharmaceuticals Aps | Formulations de daptomycine |
| CN110339342A (zh) * | 2018-04-03 | 2019-10-18 | 江苏恒瑞医药股份有限公司 | 一种达托霉素的盐或含盐的组合物及其制备方法 |
| US11058745B1 (en) | 2018-10-04 | 2021-07-13 | Good Health, Llc | Stable liquid pharmaceutical compositions of daptomycin |
| WO2021131314A1 (fr) * | 2019-12-26 | 2021-07-01 | ニプロ株式会社 | Formulation lyophilisée stable contenant de la daptomycine |
| CN115427038A (zh) | 2020-02-03 | 2022-12-02 | 建新公司 | 治疗与溶酶体贮积病相关的神经系统症状的方法 |
| WO2021183752A1 (fr) | 2020-03-12 | 2021-09-16 | Baxter International Inc. | Formulations de daptomycine contenant une association de sorbitol et de mannitol |
| AU2021311131A1 (en) | 2020-07-24 | 2023-03-23 | Genzyme Corporation | Pharmaceutical compositions comprising venglustat |
| CN115590825B (zh) * | 2022-10-20 | 2024-02-02 | 安士制药(中山)有限公司 | 一种注射用达托霉素及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5560906A (en) * | 1995-03-27 | 1996-10-01 | Oral Technology Laboratories, Inc. | Non-alcoholic antimicrobial mouthwash for removal of dental plaque |
| PL203689B1 (pl) * | 1998-09-25 | 2009-11-30 | Cubist Pharmaceuticals | Zastosowanie daptomycyny |
| US6696412B1 (en) | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
| WO2002059145A1 (fr) * | 2000-12-18 | 2002-08-01 | Cubist Pharmaceuticals, Inc. | Procedes de preparation de lipopeptides purifies |
| US7468428B2 (en) * | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
| CN1616083A (zh) * | 2004-09-01 | 2005-05-18 | 魏雪纹 | 注射用达托霉素冻干制剂及制备方法 |
| US8003673B2 (en) * | 2005-05-31 | 2011-08-23 | Cubist Pharmaceuticals, Inc. | Daptomycin for the treatment of biofilm and catheter salvage |
| TWI548414B (zh) * | 2009-11-23 | 2016-09-11 | 庫比斯特製藥有限責任公司 | 達托黴素(daptomycin)組合物及相關方法 |
| EP2504020A4 (fr) * | 2009-11-23 | 2013-05-29 | Eagle Pharmaceuticals Inc | Formulations de daptomycine |
| SI2887953T1 (en) | 2012-08-23 | 2018-02-28 | Mylan Laboratories Limited | IMPROVED DAPTOMICINE FORMATION FORMULATION |
| AU2013316779A1 (en) * | 2012-09-11 | 2015-04-02 | Hospira Australia Pty Ltd. | Daptomycin formulations and uses thereof |
-
2013
- 2013-09-11 AU AU2013316779A patent/AU2013316779A1/en not_active Abandoned
- 2013-09-11 MX MX2015003164A patent/MX366122B/es active IP Right Grant
- 2013-09-11 BR BR112015005400-5A patent/BR112015005400B1/pt active IP Right Grant
- 2013-09-11 HK HK15107795.5A patent/HK1207006A1/xx unknown
- 2013-09-11 CA CA2884484A patent/CA2884484C/fr active Active
- 2013-09-11 EP EP22169277.5A patent/EP4066849B1/fr active Active
- 2013-09-11 ES ES22169277T patent/ES3018415T3/es active Active
- 2013-09-11 DE DE13837694.2T patent/DE13837694T1/de active Pending
- 2013-09-11 ES ES13837694.2T patent/ES2552754T1/es active Pending
- 2013-09-11 NZ NZ742241A patent/NZ742241A/en unknown
- 2013-09-11 DK DK13837694.2T patent/DK2895187T1/da unknown
- 2013-09-11 HU HUE22169277A patent/HUE071031T2/hu unknown
- 2013-09-11 WO PCT/IB2013/002191 patent/WO2014041425A1/fr not_active Ceased
- 2013-09-11 PL PL22169277.5T patent/PL4066849T3/pl unknown
- 2013-09-11 NZ NZ74134213A patent/NZ741342A/en unknown
- 2013-09-11 NZ NZ706286A patent/NZ706286A/en unknown
- 2013-09-11 EP EP13837694.2A patent/EP2895187A4/fr not_active Withdrawn
- 2013-09-11 US US14/427,618 patent/US9655946B2/en active Active
- 2013-09-11 SG SG11201506113WA patent/SG11201506113WA/en unknown
-
2015
- 2015-03-10 TN TNP2015000090A patent/TN2015000090A1/fr unknown
- 2015-03-10 IL IL237652A patent/IL237652B/en active IP Right Grant
- 2015-03-11 SA SA515360129A patent/SA515360129B1/ar unknown
- 2015-03-11 CL CL2015000608A patent/CL2015000608A1/es unknown
- 2015-04-07 ZA ZA2015/02310A patent/ZA201502310B/en unknown
- 2015-11-11 HU HUE13837694A patent/HUE13837694T1/hu unknown
- 2015-11-20 CY CY20152200004T patent/CY2200004T2/el unknown
-
2017
- 2017-04-20 US US15/492,111 patent/US20170216396A1/en not_active Abandoned
-
2018
- 2018-02-23 US US15/903,764 patent/US10357535B2/en active Active
- 2018-08-17 AU AU2018217322A patent/AU2018217322B2/en active Active
-
2020
- 2020-04-15 US US16/849,387 patent/US20200237858A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1207006A1 (en) | Daptomycin formulations and uses thereof | |
| CA2883095C (fr) | Anticorps et formulations proteiques | |
| WO2014052836A3 (fr) | Procédés et compositions de traitement d'une infection | |
| WO2013184755A3 (fr) | Inhibiteurs de seca et leurs procédés de fabrication et d'utilisation | |
| ZA201500970B (en) | 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections | |
| PT2748165T (pt) | Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona e sua utilização no tratamento de infeções bacterianas | |
| ZA201307963B (en) | 1,6- diazabicyclo [3,2,1] octan-7 one derivatives and their use in the treatment of bacterial infections | |
| ZA201508529B (en) | Bacterial fermentation methods and compositions | |
| EP3033351A4 (fr) | Méthodes et compositions antivirales comprenant des molécules bactériennes probiotiques | |
| EP2971030B8 (fr) | Compositions d'oligosaccharide, glycoprotéines et procédés pour produire celles-ci dans des procaryotes | |
| WO2015058132A3 (fr) | Anticorps anti-rspo et leurs méthodes d'utilisation | |
| EP3047006A4 (fr) | Compositions assouplissantes comprenant des solutions de fruit fermentées et leurs procédés de fabrication et d'utilisation | |
| PH12014501369A1 (en) | Oral care compositions | |
| SI2575971T1 (sl) | Kombinirani rastlinski izvlečki za uporabo pri zdravljenju okužb z mikrobi | |
| EP3135755A4 (fr) | Souche de bifidobacterium breve cbt br3 pour favoriser la croissance et composition alimentaire fonctionnelle la contenant pour favoriser la croissance | |
| WO2014093999A3 (fr) | Boisson alcaline | |
| EP3165599A4 (fr) | Nouvelle bactérie d'acide lactique et composition comprenant cette bactérie d'acide lactique | |
| ZA201402452B (en) | Novel pyrimethanil formulations and uses thereof in the treatment of crops | |
| MX363631B (es) | Composiciones y metodos para tratar infecciones bacterianas. | |
| PL2753182T3 (pl) | Środki czynne przeciw szczepom Pseudomonas powodującym choroby gnilne w uprawach grzybów, ich zastosowanie i zawierające je kompozycje | |
| ZA201404826B (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
| WO2015073788A3 (fr) | Méthodes et compositions pour le traitement du cytomégalovirus humain | |
| SI2683418T1 (sl) | Produkti za vezavo bakterijskih toksinov in njihovo odstranjevanje pri zdravljenju lokalnih okužb in izdelava le-teh | |
| WO2015108605A3 (fr) | Production microbienne d'alcools à chaîne moyenne ramifiée, tels que le 4-méthylpentanol | |
| ZA201308256B (en) | Uses, methods and biological compositions of the genus paecilomyces for the control, prevention and eradication of phytoparasites in solanaceae cultures |